🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "significant breakthrough" in the effort against drug-resistant strains of the pathogen, according to scientists.

An International Health Concern

Gonorrhoea infections are escalating globally, with data suggesting more than 82 million new cases per year. Especially elevated rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, escalating drug resistance and the very limited therapeutic options currently available.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance found that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Gain Clearance

One new antibiotic, alternatively called Nuzolvence, was cleared by the US FDA in mid-December for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Scientists anticipate that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in the same week. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a innovative non-profit model for medication research. The charitable organization GARDP collaborated with the drug firm its industry partner to bring it to fruition.

“This milestone represents a major breakthrough in the management of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Research Study Results and Worldwide Availability

According to findings detailed in a prominent scientific publication, zoliflodacin cured more than 90% of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which combines a dual-drug approach. The research enrolled hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals treating patients have voiced hope. Having a one-pill regimen such as this is described as a "game-changer" for gonorrhoea control. This is considered crucial to reduce the burden of the illness for people and to prevent the spread of highly drug-resistant gonorrhoea worldwide.